| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Roche Holding AG ADR | Crenezumab - (API ADAD) | Autosomal Dominant Alzheimer's Disease (ADAD) | Phase 3 | Ongoing | Intravenous | Genetic Disorder |
| Roche Holding AG ADR | Alecensa - (ALEX) | Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | oral | Oncology |
| Roche Holding AG ADR | TECENTRIQ (atezolizumab) - IMmotion151 | Kidney cancer - renal cell carcinoma (mRCC) | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | Hemlibra - (HAVEN 6) | Hemophilia A | Phase 3 | Subcutaneous | Hematology | |
| Roche Holding AG ADR | Gazyva - (GALLIUM) | Follicular lymphoma | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-03) | Stage III Unres. Non-Small Cell Lung Cancer | Phase 3 | Intravenous | Oncology | |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-08) (China Only) | 1L Esophageal Squamous Cell Cancer | Phase 3 | Data Released | Intravenous | Oncology |
| Roche Holding AG ADR | Tiragolumab - (SKYSCRAPER-02) | 1L Extensive-Stage Small Cell Lung Cancer | Phase 3 | Intravenous | Oncology |